Nantahala Capital Management LLC increased its stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 30.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,981,980 shares of the company's stock after acquiring an additional 464,284 shares during the quarter. Nantahala Capital Management LLC owned approximately 7.12% of Vistagen Therapeutics worth $5,847,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of VTGN. R Squared Ltd acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at about $25,000. Jane Street Group LLC acquired a new stake in Vistagen Therapeutics in the third quarter valued at approximately $59,000. Virtu Financial LLC increased its holdings in shares of Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock valued at $61,000 after acquiring an additional 4,722 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Vistagen Therapeutics during the fourth quarter worth approximately $66,000. Finally, Prosperity Wealth Management Inc. bought a new position in shares of Vistagen Therapeutics in the 4th quarter worth $86,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.
Vistagen Therapeutics Trading Up 0.8 %
NASDAQ VTGN traded up $0.02 during mid-day trading on Friday, hitting $2.38. The company's stock had a trading volume of 112,389 shares, compared to its average volume of 168,865. The firm has a market capitalization of $68.69 million, a price-to-earnings ratio of -1.61 and a beta of 0.67. The company's 50 day simple moving average is $2.43 and its 200 day simple moving average is $2.70. Vistagen Therapeutics, Inc. has a twelve month low of $1.90 and a twelve month high of $4.75.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. The company had revenue of $230 billion for the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. As a group, research analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current year.
About Vistagen Therapeutics
(
Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
